BICYCLE THERAPEUTICS PLC(BCYC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,653 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
BCYC Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for BICYCLE THERAPEUTICS PLC (BCYC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCYC at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,653 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BICYCLE THERAPEUTICS PLC reports quarterly revenue of $629.0K, net income of $-50.3M, free cash flow of $-49.9M. Top institutional holders of BCYC by reported 13-F value include BAKER BROS. ADVISORS, FCPM III SERVICES B.V., ARMISTICE CAPITAL, based on the most recent SEC filings. BCYC trades on the Nasdaq exchange and files with the SEC under CIK 1761612. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCYC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BICYCLE THERAPEUTICS PLC directly from SEC EDGAR. BICYCLE THERAPEUTICS PLC's 13F Pro composite quality score has ranged between 6 and 30 since 2026, currently 25.6 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$629.0K
Net Income
Q2 2026
$-50.3M
Free Cash Flow
Q2 2026
$-49.9M
ROIC
Q2 2026
-42.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+105.8% YoYNet Income
-29.5% YoYOperating Income
-17.7% YoYEPS (Diluted)
-9.0% YoYTotal Assets
-25.0% YoYTotal Debt
Op. Cash Flow
-51.6% YoYFree Cash Flow
-51.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $72.6M +105.8% | $35.3M +30.8% | $27.0M +86.5% | $14.5M +23.6% | $11.7M +12.6% | $10.4M |
| Net Income | $-219.0M -29.5% | $-169.0M +6.4% | $-180.7M -60.3% | $-112.7M -68.7% | $-66.8M -31.0% | $-51.0M |
| Operating Income | $-247.1M -17.7% | $-209.9M -10.5% | $-189.9M -62.8% | $-116.7M -77.8% | $-65.6M -26.3% | $-52.0M |
| EPS (Diluted) | $-3.16 -9.0% | $-2.90 +42.9% | $-5.08 -33.7% | $-3.80 -42.3% | $-2.67 -0.4% | $-2.66 |
| Total Assets | $717.6M -25.0% | $956.9M +60.7% | $595.3M +45.0% | $410.6M -14.4% | $479.8M +197.7% | $161.2M |
| Total Debt | — | — | $30.7M +1.3% | $30.3M +1.5% | $29.9M +105.9% | $14.5M |
| Operating Cash Flow | $-249.7M -51.6% | $-164.7M -171.7% | $-60.6M +29.6% | $-86.1M -482.1% | $-14.8M +16.8% | $-17.8M |
| Free Cash Flow | $-252.0M -51.9% | $-166.0M -161.1% | $-63.6M +39.5% | $-105.1M -524.7% | $-16.8M +11.4% | $-19.0M |
Get alerted when BCYC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BICYCLE THERAPEUTICS PLC including:
Top Institutional Holders of BCYC
BAKER BROS. ADVISORS LP
$46.2M10,885,357 shFCPM III SERVICES B.V.
$14.7M3,468,430 shARMISTICE CAPITAL, LLC
$14.4M3,398,000 shLong Focus Capital Management, LLC
$14.0M3,310,687 shACADIAN ASSET MANAGEMENT LLC
$8.3M1,968,025 shRENAISSANCE TECHNOLOGIES LLC
$6.5M1,533,400 shGSK plc
$6.5M1,529,561 shPRICE T ROWE ASSOCIATES INC /MD/
$3.8M902,150 shMARSHALL WACE, LLP
$3.4M797,940 shQube Research & Technologies Ltd
$3.3M775,567 sh
| Fund | Value | Shares |
|---|---|---|
| BAKER BROS. ADVISORS LP | $46.2M | 10,885,357 |
| FCPM III SERVICES B.V. | $14.7M | 3,468,430 |
| ARMISTICE CAPITAL, LLC | $14.4M | 3,398,000 |
| Long Focus Capital Management, LLC | $14.0M | 3,310,687 |
| ACADIAN ASSET MANAGEMENT LLC | $8.3M | 1,968,025 |
| RENAISSANCE TECHNOLOGIES LLC | $6.5M | 1,533,400 |
| GSK plc | $6.5M | 1,529,561 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $3.8M | 902,150 |
| MARSHALL WACE, LLP | $3.4M | 797,940 |
| Qube Research & Technologies Ltd | $3.3M | 775,567 |
Companies Similar to BCYC
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Foghorn Therapeutics Inc.
Janux Therapeutics, Inc.
CYTOKINETICS INC
AGIOS PHARMACEUTICALS, INC.
Invivyd, Inc.
Autolus Therapeutics plc
REGENXBIO Inc.
Kymera Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BCYC on your watchlist
Track score changes the day BICYCLE THERAPEUTICS PLC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BCYC a good stock to buy?
13F Pro's AI-powered analysis of BICYCLE THERAPEUTICS PLC (BCYC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCYC are available on the BCYC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BCYC is classified as a small company.
Which hedge funds own BCYC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCYC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BICYCLE THERAPEUTICS PLC's investment landscape.